Emerging biotechnologies: full report - Nuffield Council on Bioethics

E m e r g i n g b i o t e c h n o l o g i e s
2011-15 delivery plan 7.42
addressing societal challenges 6.36, 7.53
general structure 7.52
public-good research 9.13
biotechnology boom 7.4, 9.5
biotechnology wager 1.1–1.3, 1.34, 4.9, 6.36,
10.4
bioterrorism Box 3.1, 8.10
botulinum toxin 3.9
bricolage 9.35
British Heart Foundation 7.18
British In Vitro Diagnostics Association 8.25
business see commercial firms; industry
Cabinet minister, proposed new 7.56, 10.17
Cambridge Antibody Technology 7.4, 9.3
cancer medicines 2.21, 2.27, 3.9, 9.51, Box 1.1
Cancer Research UK 7.18
candour, virtue of 4.50–4.51
carbon tax 9.70
Cartagena Protocol on Biosafety 8.6
caution
in approach to regulation 8.33–8.38, 8.46
virtue of 4.53–4.55, 8.34, 8.38
cells, synthetic 2.20, 2.37, Box 3.2
cellular <strong>biotechnologies</strong> 2.5–2.6
change, technological 3.22–3.25
charities
funding of research 6.14, 7.5, 7.18
governance 7.57–7.58
provision of public goods 4.8
research policy 7.18–7.19
steering direction of research 6.22
Chief Scientific Advisor, UK 6.36, 7.8
chimeric animals 3.19
chlorofluorocarbons (CFCs) Box 1.1, 3.8
choices
contingent conditions 1.21
framing effects 3.34, 3.37, Box 3.4
rational 3.21
social 5.59–5.60
Christianity 4.11–4.12
citation impact rankings 7.28
citation rates, UK research 7.24, 7.27–7.28
citizen's juries 5.36, 5.43
civil society groups 5.6, 5.16, 5.19
climate change 1.9, 2.33
clinical trials 4.49, 9.48–9.51, Box 9.3
cloned embryos 3.20
cloning, therapeutic 2.6
closures, identifying 4.38–4.40, Box 4.1
collaborative research 6.28, 6.61, 9.47
collective action/interest
public ethics 4.20–4.22
public goods 4.8
Collingridge dilemma 1.27–1.29, Box 1.2
commercial exploitation 9.1, 9.3
commercial firms
corporate social responsibility 9.53, 10.20
funding of research 6.13, 7.5
research settings 6.5
steering research directions 6.27–6.35
see also industry
commercialisation 9
addressing the obstacles 9.45–9.70
crossing the 'valley of death' 9.42–9.43
example of failure 8.13
incentivising 9.55–9.70, 10.21
intellectual property rights limiting 9.17,
9.21–9.41
rates of patents 3.5
recommendations 9.53, 9.56, 10.20–10.21
social value and 9.52–9.54, 9.56, 9.71–
9.72, 10.21
'UK is bad at' claim 7.23–7.32
see also intellectual property rights
commercial purpose 9.1
common good 4.17–4.18
communicable diseases 1.10
communication, by researchers 5.34, 6.50–
6.54, 10.10
communitarian turn 4.20
competence, technical 4.51, 5.31, 5.53–5.54
competitiveness, framing research policy 7.3
complexity
natural systems 4.13–4.14
normative 4.34–4.37
computational metaphors 2.37
computers, superintelligent 3.19
consensus, through public engagement 5.36,
5.43
consensus conferences 5.36, 5.43
consortia 9.49, Box 9.3
contingency, and its consequences 1.19–1.33
contingent conditions 1.20–1.23
contraceptive pill 3.8
Cooksey <strong>report</strong> (2006) 9.42
cooperative research see collaborative
research
corporate social responsibility 9.53, 10.20
cosmetics 2.28, 3.9
counterfactuals 1.16–1.18
crop impact fund 9.68
crowded-out alternatives 1.26, 1.28, 1.31
crowdsourcing 9.50, Box 9.3
cultivation analysis 2.38, 5.11
Darwinian evolution 4.12
David, Paul 1.2, 2.33, 3.23
dedicated biotechnology firms (DBFs) 9.10–
9.12
dehumanising consequences 2.34, 4.16
deliberative mapping 5.36
deliberative polling 5.37
democracy 5.25
Department for Business, Innovation and Skills
(BIS) 7.14, 7.50, 7.52, 7.54, 10.17
I N D E X
199